Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing ...

According to the claim, the Ayurvedic formulation is made from traditional ingredients mentioned in classical texts. Patanjali states that it works at the molecular level in research settings.

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

Sydney, Australia Monday, March 16, 2026, 10:00 Hrs [IST] ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Candel Therapeutics (CADL) stock rises as the company updates results from an ongoing mid-stage trial for its lead candidate, CAN-2409 in lung cancer. Read more here.

Study to test RC220 alongside standard-of-care osimertinib to prevent or delay treatment resistance. ... Read More The post ...